In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Mersana Therapeutics Inc’s stock clocked out at $0.39, up 4.78% from its previous closing price of $0.37. In other words, the price has increased by $4.78 from its previous closing price. On the day, 2.7 million shares were traded.
Ratios:
To gain a deeper understanding of MRSN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.83 and its Current Ratio is at 1.83.
JP Morgan Upgraded its Underweight to Neutral on March 19, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 16 ’25 when Mandelia Ashish sold 3,554 shares for $0.58 per share. The transaction valued at 2,061 led to the insider holds 57,519 shares of the business.
Protopapas Anna sold 8,637 shares of MRSN for $5,009 on Jan 16 ’25. The Director now owns 168,041 shares after completing the transaction at $0.58 per share. On Jan 16 ’25, another insider, Lowinger Timothy B, who serves as the SVP, Chief Sci.&Tech. Officer of the company, sold 8,048 shares for $0.58 each. As a result, the insider received 4,668 and left with 257,673 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.41.
Stock Price History:
Over the past 52 weeks, MRSN has reached a high of $2.83, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is 9.79%, while the 200-Day Moving Average is calculated to be -67.22%.
Shares Statistics:
A total of 124.63M shares are outstanding, with a floating share count of 96.84M. Insiders hold about 22.30% of the company’s shares, while institutions hold 50.20% stake in the company.
